<DOC>
	<DOCNO>NCT02975752</DOCNO>
	<brief_summary>First-line treatment afatinib prolongs overall survival patient metastatic non-small-cell lung cancer ( NSCLC ) harbor EGFR exon 19 deletion mutation . Conversely , somatic KRAS mutation negative predictor benefit EGFR-targeting agent . In study want compare new highly sensitive method detection EGFRdelEx19 KRAS Exon 2 targeted-resequencing multiplex-PCR ( NGS ) .</brief_summary>
	<brief_title>EGFRdelEx19 KRAS Exon 2 Mutation Detection EBUS-TBNA</brief_title>
	<detailed_description>First-line treatment afatinib prolongs overall survival patient metastatic non-small-cell lung cancer ( NSCLC ) harbor EGFR exon 19 deletion mutation . Conversely , somatic KRAS mutation negative predictor benefit EGFR-targeting agent . Rapid availability biomarker result mandatory prevent delay inferior treatment . Endobronchial ultrasound-guided transbronchial needle aspiration ( EBUS-TBNA ) well-established lung cancer diagnosis stag . Next generation sequencing ( NGS ) via target resequencing allow simultaneous interrogation multiple mutation , limitation base amount tumor tissue require assay time . RT-PCR use Light-Cycler technology ( LC-RTPCR ) rapid sensitive assay detect somatic mutation various tissue NSCLC patient . The study 's aim analyze LC-RTPCR feasible rapid EGFRdelEx19 KRAS Exon 2 mutation detection EBUS-TBNA sample compare result result obtain via standard NGS mutation analysis .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>lung adenocarcinoma positive EBUSTBNA specimen diagnosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>